Posted by Michael Wonder on 20 Apr 2022
NICE terminates appraisal of nivolumab
20 April 2022 - This is the first appraisal of nivolumab to be terminated by NICE.
NICE is unable to make a recommendation on the use nivolumab (Opdivo) in combination with cabozantinib maleate for patients with untreated advanced renal cell carcinoma.
This is because BMS withdrew the evidence submission.
